Skip to content

Press Releases

 
Press Releases
All Releases
Mar 20, 2017
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those with ASCVD and/or HeFH - - On Track to Submit NDA for an LDL-C Lowering Indication by 1H 201...
Mar 7, 2017
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced t...
Mar 6, 2017
Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time ANN ARBOR, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral t...
Feb 22, 2017
ANN ARBOR, Mich., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bem...
Feb 15, 2017
Fireside Chat Webcast on Wednesday, February 22, 2017 at 8:00 a.m. Eastern Time ANN ARBOR, Mich., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for ...
Jan 25, 2017
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD RiskTop-Line Results Expected by Q2 2018 ANN ARBOR, Mich., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Esperion Thera...
Jan 9, 2017
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced the initiation of the global...
Jan 8, 2017
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevate...
Jan 4, 2017
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced that president and chief executive officer,...
= add release to Briefcase